Case report of a renal cell carcinoma patient with acute pancreatitis under both sunitinib and axitinib treatment

Sunitinib and axitinib are oral tyrosine kinase inhibitors (TKI) that is commonly used in the treatment of metastatic renal cell carcinoma (RCC) as it has been shown to improve the progression-free survival of patients compared with sorafenib. Hypertension, palmar-plantar erythrodysesthesia, diarrhe...

Full description

Bibliographic Details
Published in:	Journal of Oncological Sciences
Main Authors:	Utku Oflazoglu, Umut Varol, Ahmet Alacacioglu, Tarik Salman, Necla Demir, Huseyin Salih Semiz, Aziz Karaoglu, Ilhan Oztop
Format:	Article
Language:	English
Published:	Turkish Society of Oncology 2016-08-01
Subjects:	Sunitinib Axitinib Renal cell carcinoma Pancreatitis Side effects
Online Access:	http://www.sciencedirect.com/science/article/pii/S2452336416300267

Similar Items

Cost-effectiveness and budget impact of pembrolizumab+axitinib versus sunitinib in patients with advanced clear-cell renal cell carcinoma in the Netherlands
by: Nicolas S. H. Xander, et al.
Published: (2023-06-01)

The use of a new combination of avelumab + axitinib in patients with metastatic kidney cancer in the first line of treatment
by: B. Ya. Alekseev, et al.
Published: (2021-06-01)

Understanding Treatment Decisions and Management for Patients with Advanced Renal Cell Carcinoma Using Hypothetical Case Studies: A Vodcast
by: Benjamin Garmezy, et al.
Published: (2024-10-01)

Losartan Alleviates the Side Effects and Maintains the Anticancer Activity of Axitinib
by: Ying Fu, et al.
Published: (2022-04-01)

Solvates and Polymorphs of Axitinib: Characterization and Phase Transformation
by: Yinhu Pan, et al.
Published: (2024-10-01)

Design, Synthesis, and Biological Evaluation of Axitinib Derivatives
by: Na Wei, et al.
Published: (2018-03-01)

Axitinib, cabozantinib, or everolimus in the treatment of prior sunitinib-treated patients with metastatic renal cell carcinoma: results of matching-adjusted indirect comparison analyses
by: Irina Proskorovsky, et al.
Published: (2018-12-01)

UPLC-MS/MS analysis of axitinib and pharmacokinetic application in beagle dogs
by: Hengyu Bi, et al.
Published: (2024-10-01)

Adverse drug reactions associated with sunitinib therapy: Characteristics and risk factors
by: Mugoša Snežana, et al.
Published: (2021-01-01)

Axitinib in metastatic renal cell carcinoma: single center experience
by: Agnieszka Buraczewska, et al.
Published: (2017-01-01)

Axitinib in sequential therapy in metastatic renal cell carcinoma
by: Agata Kuchar, et al.
Published: (2015-05-01)

Systemic hypertension with VEGFR inhibitor (axitinib) therapy in cancer patients: A meta-analysis and systematic review of randomized controlled trials
by: Aravind Dilli Babu, et al.
Published: (2024-06-01)

Response to Combination of Pembrolizumab and Axitinib in Hereditary Leyomiomatosis and Renal Cell Cancer (HLRCC)
by: Ibon Gurruchaga Sotés, et al.
Published: (2021-06-01)

Oxidative stress suppression contributes to antiseizure action of axitinib and rapamycin in pentylenetetrazol-induced kindling
by: O. B. Poshyvak, et al.
Published: (2021-04-01)

Efficacy of combination therapy with pembrolizumab and axitinib for metastatic renal collecting duct cell carcinoma: A report on two cases
by: Shinji Tamada, et al.
Published: (2022-11-01)

Phase Separation Investigation of Axitinib in Supersaturated Solution
by: Jie Xu, et al.
Published: (2024-11-01)

Theoretical investigation of fullerene (C60) as nano carrier for anti-cancer drug Axitinib
by: Saied Jamaladdin Emamjome Koohbanani, et al.
Published: (2024-03-01)

Potential for use sunitinib in pancreatic neuroendocrine tumors
by: A. A. Markovich, et al.
Published: (2019-06-01)

Anti-angiogenic and antioxidant effects of axitinib in human retinal endothelial cells: implications in diabetic retinopathy
by: Francesca Lazzara, et al.
Published: (2024-06-01)

Case report: Pembrolizumab plus Axitinib related hypothyroid myopathy in two kidney cancer patients
by: Andrea Boutros, et al.
Published: (2022-12-01)

Exploring the multifaceted antitumor activity of axitinib in lung carcinoids
by: Monica Oldani, et al.
Published: (2024-07-01)

A case of hyperammonemia occurring during treatment of metastatic renal cell carcinoma with axitinib
by: Shoichi Kimura, et al.
Published: (2023-07-01)

Pazopanib in the treatment of advanced renal cell carcinoma
by: M. I. Volkova, et al.
Published: (2018-11-01)

Complete remission of brain metastases in renal cell carcinoma treated with axitinib after failure with nivolumab and ipilimumab treatment
by: Koichiro Takayama, et al.
Published: (2022-11-01)

Axitinib as a third or further line of treatment in renal cancer: a single institution experience
by: G. Tsironis, et al.
Published: (2020-06-01)

Influence of genetic polymorphisms in vascular endothelial-related genes on the clinical outcome of axitinib in patients with metastatic renal cell carcinoma
by: Kazuyuki Numakura, et al.
Published: (2024-12-01)

A significant response to sunitinib in a patient with anaplastic thyroid carcinoma
by: Enrique Grande, et al.
Published: (2013-01-01)

Axitinib targets cardiac fibrosis in pressure overload-induced heart failure through VEGFA-KDR pathway
by: Tiantian Jiao, et al.
Published: (2023-11-01)

Evaluation of β-Catenin Inhibition of Axitinib and Nitazoxanide in Human Monocyte-Derived Dendritic Cells
by: Waqas Azeem, et al.
Published: (2021-08-01)

Epithelioid Angiomyolipoma with Tumor Thrombus into Inferior Vena Cava Presurgically Treated with Combination Therapy of Pembrolizumab and Axitinib: A Case Report
by: Kawasoe C, et al.
Published: (2023-10-01)

Intralesional Axitinib Injection Mitigates Hypertrophic Scar by Inhibiting Angiogenesis Pathway: A Preliminary Study in a Rabbit Ear Model
by: Liu C, et al.
Published: (2023-10-01)

Axitinib in the treatment of renal cell carcinoma: design, development, and place in therapy
by: Bellesoeur A, et al.
Published: (2017-09-01)

Sunitinib for adenocarcinoma of the rete testis: a case report
by: Kezhen Li, et al.
Published: (2024-04-01)

Prognostic relevance of sunitinib toxicities and comparison of continuous vs. intermittent sunitinib dosing schedule in metastatic renal cell cancer patients
by: Çetin Ordu, et al.
Published: (2016-06-01)

Sunitinib in pancreatic neuroendocrine tumors. Clinical case
by: A. A. Markovich, et al.
Published: (2019-12-01)

Sintilimab combined with axitinib in the treatment of advanced chromophobe renal cell carcinoma: a case report
by: Huimin Zhang, et al.
Published: (2024-02-01)

Effect of enhanced expression of connexin 43 on sunitinib-induced cytotoxicity in mesothelioma cells
by: Miaki Uzu, et al.
Published: (2015-05-01)

Biological Role of Pazopanib and Sunitinib Aldehyde Derivatives in Drug-Induced Liver Injury
by: Maud Maillard, et al.
Published: (2022-09-01)

Final Report of the First Refractory Germ Cell Tumor Treated with Sunitinib Malate
by: Joan Manel Gasent Blesa, et al.
Published: (2009-12-01)

Nephrotic Syndrome and Acute Renal Failure Apparently Induced by Sunitinib
by: Ying-Shou Chen, et al.
Published: (2009-10-01)